Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population
The survival rate for patients with hematologic malignancies has been greatly improved by the development of targeted therapy, immunotherapy, and transplantation [1 –3]. Particularly, allogeneic stem cell transplantation (alloSCT) has been identified as a curative treatment modality in hematologic malignancies [2], improving the 3-year overall survival (OS) of leukemia patients to 60–70% [4,5]. (Source: Leukemia Research)
Source: Leukemia Research - April 3, 2018 Category: Hematology Authors: Hyunkyung Park, Yoo Jin Lee, Sang-Jin Shin, Jayoun Lee, Silvia Park, Inho Kim, Joon-ho Moon, Hyewon Lee, Jun Ho Jang, Sung-Soo Yoon, Youngil Koh Source Type: research
Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population
(Source: Leukemia Research)
Source: Leukemia Research - April 3, 2018 Category: Hematology Authors: Hyunkyung Park, Yoo Jin Lee, Sang-Jin Shin, Jayoun Lee, Silvia Park, Inho Kim, Joon-ho Moon, Hyewon Lee, Jun Ho Jang, Sung-Soo Yoon, Youngil Koh Source Type: research
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up
Thrombosis is the most relevant determinant of morbidity and mortality in Polycythemia Vera (PV) patients and the reported rates of thrombosis occurrence have not significantly improved over last decades. To date, many clinical studies focused on factors predicting thrombotic complications and survival [1 –7]; whereas a general agreement exists on the prognostic role of age>60 years and previous thrombotic events, some other clinical (white blood cell [WBC] and platelet (PLT) counts, cardiovascular [CV] risk factors) and biological factors (JAK2 V617F mutation, allele burden, abnormal karyotype) have been evaluated wi...
Source: Leukemia Research - March 31, 2018 Category: Hematology Authors: Ambra Di Veroli, Francesco Buccisano, Alessandro Andriani, Marco Montanaro, Roberto Latagliata, Cristina Santoro, Massimo Breccia, Francesca Spirito, Michele Cedrone, Barbara Anaclerico, Sabrina Leonetti Crescenzi, Raffaele Porrini, Marianna De Muro, Gius Tags: Letter to the Editor Source Type: research
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis Of 623 PTS With long follow-up
(Source: Leukemia Research)
Source: Leukemia Research - March 31, 2018 Category: Hematology Authors: Ambra Di Veroli, Francesco Buccisano, Alessandro Andriani, Marco Montanaro, Roberto Latagliata, Cristina Santoro, Massimo Breccia, Francesca Spirito, Michele Cedrone, Barbara Anaclerico, Sabrina Leonetti Crescenzi, Raffaele Porrini, Marianna De Muro, Gius Tags: Letter to the Editor Source Type: research
Secreted Wnt antagonists in leukemia: A road yet to be paved
The first description of deregulated Wnt signaling in a hematological malignancy was reported in chronic myeloid leukemia (CML) [1]. CML is a clonal hematopoietic stem cell (HSC) disease characterized clinically by an increase in myeloid lineage cells at all stages of differentiation. The translocation −t(9;22)(q34;q11)- leading to the formation of the Philadelphia chromosome (derivative 22) is the hallmark of CML. This translocation results in the fusion of the proto-oncogene ABL located on the long arm of chromosome 9, with the BCR gene on chromosome 22 [2]. (Source: Leukemia Research)
Source: Leukemia Research - March 28, 2018 Category: Hematology Authors: Melek Pehlivan, Ceyda Çalışkan, Zeynep Yüce, Hakki Ogun Sercan Source Type: research
Secreted Wnt antagonists in Leukemia: A road yet to be paved
(Source: Leukemia Research)
Source: Leukemia Research - March 28, 2018 Category: Hematology Authors: Melek Pehlivan, Ceyda Çalışkan, Zeynep Yüce, Hakki Ogun Sercan Source Type: research
Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia
Essential thrombocythemia (ET) is one of the myeloproliferative neoplasms characterized by abnormal bone marrow megakaryocyte proliferation, elevated platelet count and a tendency to develop vascular complications, including thrombosis and hemorrhage. Age, WBC count and thrombotic history have been confirmed as independent risk factors for future thrombotic events in previous studies. One of these studies also identified cardiovascular (CV) risk factors and JAK2 V617F mutation as prognostic marker for future thrombosis when adhering to the recent International Prognostic Score for Thrombosis in ET (IPSET-thrombosis) [1]. (...
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: Dian Zhou, Wei Chen, Hai Cheng, Jian-lin Qiao, Li-li Zhu, Zhen-yu Li, Kai-lin Xu Tags: Research paper Source Type: research
Lifetime physical inactivity is associated with increased risk for Hodgkin and non-Hodgkin lymphoma: A case-control study
The two most common subtypes of lymphoma, Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), are estimated to account for 0.5% and 4.3% of all new cancer cases and 0.2% and 3.4% of all cancer deaths respectively in the United States in 2017 [1,2]. Well-established unmodifiable risk factors for both HL and NHL include immunosuppression, immunodeficiency, age and sex, with men being disproportionately affected. Additional NHL risk factors include autoimmune disorders, such as rheumatoid arthritis and Sj ögren syndrome, as well as bacterial infections, such as Helicobacter pylori [3,4]. (Source: Leukemia Research)
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: John Lewis Etter, Rikki Cannioto, Kah Teong Soh, Emad Alquassim, Hani Almohanna, Zachary Dunbar, Janine M. Joseph, Sophia Balderman, Francisco Hernandez-Ilizaliturri, Kirsten B. Moysich Source Type: research
Lenalidomide treatment in lower risk myelodysplastic syndromes —The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)
The most common cytogenetic abnormality of MDS is the deletion of the long arm of chromosome 5 (del(5q)), which occurs in nearly 30% of MDS patients [1]. The group of patients with this aberration is relatively heterogeneous with regard to clinical manifestation, although this depends on other factors such as bone marrow myeloblast count, additional cytogenetic aberrations, and the presence of mutations and cytopenias (especially thrombocytopenia) [2 –5]. A special categorization is reserved among the subgroups of MDS for patients with isolated del(5q) without increased blasts. (Source: Leukemia Research)
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: Anna Jonasova, Radana Neuwirtova, Helena Polackova, Magda Siskova, Tomas Stopka, Eduard Cmunt, Monika Belickova, Alena Moudra, Lubomir Minarik, Ota Fuchs, Kyra Michalova, Zuzana Zemanova Tags: Research paper Source Type: research
Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway
Acute myeloid leukemia (AML) is a hematological malignancy that mainly originates from the bone marrow, with affected cells displaying myeloid characteristics. AML cells fail to undergo terminal differentiation and remain immature and proliferative. Process of terminal differentiation could be blocked by deregulation of transcription factors, such as RUNX1 and PU.1 (encoded by SPI-1 gene), that control myeloid differentiation. Mutations or reduced expression of these transcription factors were able to potentiate the development of AML [1,2]. (Source: Leukemia Research)
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: Chung Fan Lam, Hoi Ting Yeung, Yuk Man Lam, Ray Kit Ng Tags: Research paper Source Type: research
Reactive Oxygen Species Activate Differentiation Gene Transcription of Acute Myeloid Leukemia Cells via the JNK/c-JUN Signaling Pathway
(Source: Leukemia Research)
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: Chung Fan Lam, Hoi Ting Yeung, Yuk Man Lam, Ray Kit Ng Tags: Research paper Source Type: research
Clinico-Hematological Profile and Thrombotic/Hemorrhagic Events in 150 Chinese Patients with Essential Thrombocythemia
(Source: Leukemia Research)
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: Dian Zhou, Wei Chen, Hai Cheng, Jian-lin Qiao, Li-li Zhu, Zhen-yu Li, Kai-lin Xu Tags: Research paper Source Type: research
Lifetime physical inactivity is associated with increased risk for Hodgkin and non-Hodgkin lymphoma: A case-control study
(Source: Leukemia Research)
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: John Lewis Etter, Rikki Cannioto, Kah Teong Soh, Emad Alquassim, Hani Almohanna, Zachary Dunbar, Janine M. Joseph, Sophia Balderman, Francisco Hernandez-Ilizaliturri, Kirsten B. Moysich Source Type: research
Lenalidomide Treatment in Lower Risk Myelodysplastic Syndromes – the experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)
(Source: Leukemia Research)
Source: Leukemia Research - March 27, 2018 Category: Hematology Authors: Anna Jonasova, Radana Neuwirtova, Helena Polackova, Magda Siskova, Tomas Stopka, Eduard Cmunt, Monika Belickova, Alena Moudra, Lubomir Minarik, Ota Fuchs, Kyra Michalova, Zuzana Zemanova Tags: Research paper Source Type: research
Corrigendum to: Comparison of Induction Therapy in Non-high Risk Acute Promyelocytic Leukemia with Arsenic Trioxide or in Combination with ATRA Leukemia Research 66 (2018) 85 –88
Regarding the survival results, please note that the 2.5-year disease free survival and overall survival in ATO group were 60% and 86% respectively and in ATO plus ATRA group, both disease-free survival and overall survival were 100%. (Source: Leukemia Research)
Source: Leukemia Research - March 20, 2018 Category: Hematology Authors: Ardeshir Ghavamzadeh, Mahdi Jalili, Sharbanoo Rostami, Marjan Yaghmaie, Leyla Sharifi Aliabadi, Seyed Asadollah Mousavi, Mohammad Vaezi, Hossein Kamranzadeh Fumani, Mohammad Jahani, Kamran Alimoghaddam Source Type: research
